The use of selenium and vitamin E supplementation to prevent recurrence of non-muscle-invasive bladder cancer: results of the SELENIB trial
BAUS ePoster online library. Bryan R. 06/24/19; 259508; P2-4
Mr. Richard Bryan
Mr. Richard Bryan
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)

The SELENIB trial aimed to determine whether selenium or vitamin E could prevent recurrence in non-muscle-invasive bladder cancer (NMIBC) patients.


A double-blind randomized placebo-controlled 2x2 factorial trial aimed to recruit 515 newly-diagnosed NMIBC patients between 17/07/2007 and 10/10/2011 (REC approval 06/MRE04/65). Eligibility included a new diagnosis of NMIBC; randomisation within 12months of initial transurethral resection was required. Four possible interventions were oral selenium (200mcg/day high-selenium yeast) and vitamin E placebo, vitamin E (200IU/day d-alpha-tocopherol) and selenium placebo, selenium and vitamin E, or placebo and placebo for 5 years. Patients were otherwise treated according to contemporaneous guidelines. Primary outcome was recurrence-free interval. Secondary outcomes included progression-free interval and overall survival. A stratified log rank test was performed for comparing each supplement to placebo while stratifying for the other; hazard ratios were obtained using Cox's regression model.


We recruited 270 patients, with median follow-up of 5.4yrs and median duration of treatment of 1.5yrs. For selenium versus no selenium, no statistically significant difference in recurrence-free interval was observed, HR 0.92 (95% CI 0.65, 1.32, p=0.655). For vitamin E versus no vitamin E, vitamin E was associated with a statistically significant increase in risk of recurrence, HR 1.46 (95% CI 1.02, 2.09, p=0.039). No significant differences were observed for progression-free interval or overall survival with either supplement.


Selenium supplementation did not influence recurrence, progression or survival. Vitamin E supplementation was associated with an increased risk of recurrence in NMIBC patients, but did not influence progression or overall survival.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings